ARTEBONE Bone Void Filler in Arthrodesis Procedure of the Ankle
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
ARTEBONE
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Primary or secondary osteoarthritis, fusion of the ankle
Eligibility Criteria
Inclusion Criteria:
- The patient has signed the independent ethics committee approved informed consent form specific to this investigation prior to enrollment.
- The patient is diagnosed with primary or secondary osteoarthritis requiring fusion of the ankle joint (tibiotalar) or the subtalar joint.
- The fusion site should be able to be rigidly stabilized with two or three screws across the fusion site.
- The patient is independent, ambulatory, and could comply with all post-operative evaluations and visits.
- The patient is at least 18 years of age and considered to be skeletally mature.
Exclusion Criteria:
- The patient has undergone previous fusion surgery of the proposed fusion site.
- The fusion site requires other than screw fixation, more than three screws across the fusion site to achieve rigid fixation, or more than one kit (3 cc) of graft material.
- There is radiographic evidence of bone cysts, segmental defects or growth plate fracture around the fusion site that may negatively impact bony fusion.
- The patient currently has untreated malignant neoplasm(s) at the surgical site, or is currently undergoing radio- or chemotherapy.
- The patient has severe diabetes with neuropathy.
- The patient has a metabolic disorder known to adversely affect the skeleton, other than primary osteoporosis or diabetes (e.g., renal osteodystrophy or hypercalcemia).
- The patient uses chronic medications known to affect the skeleton (e.g., glucocorticoid usage > 10 mg/day).
- The patient uses immunosuppressive treatment or medication for osteoporosis.
- The patient has systemic or severe local inflammation or infections.
- The patient has a pre-fracture neuromuscular or musculoskeletal deficiency which might limit the ability to perform objective functional measurements.
- The patient is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the investigator judges the patient to be unable or unlikely to remain compliant.
- The patient has an allergy to reindeer protein.
- The patient has received an investigational therapy or approved therapy for investigational use within 30 days of surgery.
- The patient is a prisoner, known or suspected to be transient, or has a history of drug/alcohol abuse within the 12 months prior to screening for study entry.
- The patient is pregnant or a female intending to become pregnant during the study period.
- The patient is deemed morbidly obese (body mass index [BMI] > 45 kg/m2).
- The patient has a recent history of smoking during the past six months prior to screening for study entry.
Sites / Locations
- Central Hospital of Central Finland
- South Karelia Central Hospital
- Oulu University Hospital
- Helsinki University Central Hospital Peijas
- Autonomous Public Clinical Hospital No. 1 of Pomeranian Medical University in Szczecin named after professor Tadeusz Sokołowski
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ARTEBONE
Arm Description
Bone Void Filler
Outcomes
Primary Outcome Measures
The incidence of unanticipated serious adverse device effects
Bone fusion rates
Bone fusion rates assessed by sequential post-operative radiographs and Computer tomography at 6 months (both evaluated by two independent radiologists).
Bone fusion rates
Bone fusion rates assessed by sequential post-operative radiographs at 12 months (evaluated by two independent radiologists).
Secondary Outcome Measures
Adverse events
Adverse events recorded either voluntarily by the subject in response to a non-leading question (i.e. "how have you been feeling?") or following a clinical observation.
All adverse events will be assessed by the investigator according to their severity, relationship to the investigational product, action taken, and outcome status as defined in the ISO14155 guideline.
Time-points for returning to work
Secondary performance endpoint
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Functional performance at 6 months, secondary performance endpoint
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Functional performance at 12 months, secondary performance endpoint
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Secondary performance endpoint
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Secondary performance endpoint
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Secondary performance endpoint
Full Information
NCT ID
NCT02480868
First Posted
April 9, 2015
Last Updated
December 19, 2017
Sponsor
BBS-Bioactive Bone Substitutes Oy
1. Study Identification
Unique Protocol Identification Number
NCT02480868
Brief Title
ARTEBONE Bone Void Filler in Arthrodesis Procedure of the Ankle
Official Title
A Prospective Clinical Investigation to Assess Safety and Performance of ARTEBONE as Bone Void Filler in a Single Arthrodesis Procedure of the Ankle (Ankle Joint or Subtalar Joint)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
January 2014 (Actual)
Primary Completion Date
December 14, 2017 (Actual)
Study Completion Date
December 14, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BBS-Bioactive Bone Substitutes Oy
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this investigation is to assess safety and performance of ARTEBONE Bone Void Filler in the single arthrodesis procedure.
Detailed Description
This is a multi-centre, prospective clinical investigation in subjects in need of a single arthrodesis procedure of the ankle (ankle joint or subtalar joint) to relieve persistent pain due to primary or secondary osteoarthritis.
The objectives of the study are to assess safety and performance of ARTEBONE as Bone Void Filler in the single arthrodesis procedure of the ankle (ankle joint or subtalar joint).
The study will be monitored regularly by Clinical Research Associates (CRAs). Monitoring procedures include one or more visits designed to clarify all prerequisites before the study commences. Interim monitoring visits will take place on a regular basis according to a schedule fixed by mutual agreement. During these visits, the CRA will check for completion of the entries on the Case Report Forms (CRFs), their compliance with the Clinical Investigation Plan (CIP), the standard operating procedures (SOP), Good Clinical Practice and International Organization for Standardization 14155 (ISO 14155), and will compare the CRF entries with the source data, as well as update the Investigator´s File (IF).
Source data verification will be performed in an unassisted way (direct access to source documents), unless otherwise required by the local ethics committee.
The sample size of 30 subjects was considered adequate for the safety and performance evaluation in this indication based on earlier discussions with the authorities.
An interim analyses will be performed for 6 months data. There will be descriptive analysis only and comparison to literature. Literature search has been done according to European Union (EU) guidelines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Primary or secondary osteoarthritis, fusion of the ankle
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ARTEBONE
Arm Type
Experimental
Arm Description
Bone Void Filler
Intervention Type
Device
Intervention Name(s)
ARTEBONE
Intervention Description
4,3 g Bone Void Filler
Primary Outcome Measure Information:
Title
The incidence of unanticipated serious adverse device effects
Time Frame
Before or at 12 months
Title
Bone fusion rates
Description
Bone fusion rates assessed by sequential post-operative radiographs and Computer tomography at 6 months (both evaluated by two independent radiologists).
Time Frame
At 6 months (plus or minus 2 weeks)
Title
Bone fusion rates
Description
Bone fusion rates assessed by sequential post-operative radiographs at 12 months (evaluated by two independent radiologists).
Time Frame
At 12 months (plus or minus 2 weeks)
Secondary Outcome Measure Information:
Title
Adverse events
Description
Adverse events recorded either voluntarily by the subject in response to a non-leading question (i.e. "how have you been feeling?") or following a clinical observation.
All adverse events will be assessed by the investigator according to their severity, relationship to the investigational product, action taken, and outcome status as defined in the ISO14155 guideline.
Time Frame
Within 12 months
Title
Time-points for returning to work
Description
Secondary performance endpoint
Time Frame
Within 12 months
Title
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Description
Functional performance at 6 months, secondary performance endpoint
Time Frame
6 months (plus or minus 2 weeks)
Title
Functional performance (Scores of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale)
Description
Functional performance at 12 months, secondary performance endpoint
Time Frame
12 months (plus or minus 2 weeks)
Title
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Description
Secondary performance endpoint
Time Frame
12 weeks (plus or minus 1 week)
Title
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Description
Secondary performance endpoint
Time Frame
6 months (plus or minus 2 weeks)
Title
Subjective pain evaluation (VAS) for fusion site and at weight bearing
Description
Secondary performance endpoint
Time Frame
12 months (plus or minus 2 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient has signed the independent ethics committee approved informed consent form specific to this investigation prior to enrollment.
The patient is diagnosed with primary or secondary osteoarthritis requiring fusion of the ankle joint (tibiotalar) or the subtalar joint.
The fusion site should be able to be rigidly stabilized with two or three screws across the fusion site.
The patient is independent, ambulatory, and could comply with all post-operative evaluations and visits.
The patient is at least 18 years of age and considered to be skeletally mature.
Exclusion Criteria:
The patient has undergone previous fusion surgery of the proposed fusion site.
The fusion site requires other than screw fixation, more than three screws across the fusion site to achieve rigid fixation, or more than one kit (3 cc) of graft material.
There is radiographic evidence of bone cysts, segmental defects or growth plate fracture around the fusion site that may negatively impact bony fusion.
The patient currently has untreated malignant neoplasm(s) at the surgical site, or is currently undergoing radio- or chemotherapy.
The patient has severe diabetes with neuropathy.
The patient has a metabolic disorder known to adversely affect the skeleton, other than primary osteoporosis or diabetes (e.g., renal osteodystrophy or hypercalcemia).
The patient uses chronic medications known to affect the skeleton (e.g., glucocorticoid usage > 10 mg/day).
The patient uses immunosuppressive treatment or medication for osteoporosis.
The patient has systemic or severe local inflammation or infections.
The patient has a pre-fracture neuromuscular or musculoskeletal deficiency which might limit the ability to perform objective functional measurements.
The patient is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the investigator judges the patient to be unable or unlikely to remain compliant.
The patient has an allergy to reindeer protein.
The patient has received an investigational therapy or approved therapy for investigational use within 30 days of surgery.
The patient is a prisoner, known or suspected to be transient, or has a history of drug/alcohol abuse within the 12 months prior to screening for study entry.
The patient is pregnant or a female intending to become pregnant during the study period.
The patient is deemed morbidly obese (body mass index [BMI] > 45 kg/m2).
The patient has a recent history of smoking during the past six months prior to screening for study entry.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juhana Leppilahti, Professor
Organizational Affiliation
Oulu University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Central Hospital of Central Finland
City
Jyväskylä
ZIP/Postal Code
40620
Country
Finland
Facility Name
South Karelia Central Hospital
City
Lappeenranta
ZIP/Postal Code
53101
Country
Finland
Facility Name
Oulu University Hospital
City
Oulu
ZIP/Postal Code
90220
Country
Finland
Facility Name
Helsinki University Central Hospital Peijas
City
Vantaa
ZIP/Postal Code
00029
Country
Finland
Facility Name
Autonomous Public Clinical Hospital No. 1 of Pomeranian Medical University in Szczecin named after professor Tadeusz Sokołowski
City
Szczecin
ZIP/Postal Code
71252
Country
Poland
12. IPD Sharing Statement
Learn more about this trial
ARTEBONE Bone Void Filler in Arthrodesis Procedure of the Ankle
We'll reach out to this number within 24 hrs